CAR-T–cell therapy normally requires the patient’s own healthy T cells. An allogeneic CAR-T bridging therapy could rescue lymphopenic patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058233 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2018017004 | DOI Listing |
Publication Analysis
Top Keywords
sequential allogeneic
4
allogeneic autologous
4
autologous car-t-cell
4
car-t-cell therapy
4
therapy treat
4
treat immune-compromised
4
immune-compromised leukemic
4
leukemic patient
4
patient car-t–cell
4
car-t–cell therapy
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!